Biogen Inc. (BIIB)
NASDAQ: BIIB · Real-Time Price · USD
187.57
+3.73 (2.03%)
Mar 30, 2026, 4:00 PM EDT - Market closed
Biogen Revenue
In the year 2025, Biogen had annual revenue of $9.89B with 2.22% growth. Biogen had revenue of $2.28B in the quarter ending December 31, 2025, a decrease of -7.14%.
Revenue (ttm)
$9.89B
Revenue Growth
+2.22%
P/S Ratio
2.78
Revenue / Employee
$1,318,747
Employees
7,500
Market Cap
27.53B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 9.89B | 214.70M | 2.22% |
| Dec 31, 2024 | 9.68B | -159.70M | -1.62% |
| Dec 31, 2023 | 9.84B | -337.80M | -3.32% |
| Dec 31, 2022 | 10.17B | -808.30M | -7.36% |
| Dec 31, 2021 | 10.98B | -2.46B | -18.32% |
| Dec 31, 2020 | 13.44B | -933.30M | -6.49% |
| Dec 31, 2019 | 14.38B | 925.00M | 6.88% |
| Dec 31, 2018 | 13.45B | 1.18B | 9.61% |
| Dec 31, 2017 | 12.27B | 825.10M | 7.21% |
| Dec 31, 2016 | 11.45B | 685.00M | 6.36% |
| Dec 31, 2015 | 10.76B | 1.06B | 10.93% |
| Dec 31, 2014 | 9.70B | 2.77B | 39.97% |
| Dec 31, 2013 | 6.93B | 1.42B | 25.66% |
| Dec 31, 2012 | 5.52B | 467.83M | 9.27% |
| Dec 31, 2011 | 5.05B | 332.21M | 7.04% |
| Dec 31, 2010 | 4.72B | 339.08M | 7.75% |
| Dec 31, 2009 | 4.38B | 279.84M | 6.83% |
| Dec 31, 2008 | 4.10B | 925.89M | 29.19% |
| Dec 31, 2007 | 3.17B | 488.57M | 18.21% |
| Dec 31, 2006 | 2.68B | 260.55M | 10.76% |
| Dec 31, 2005 | 2.42B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Merck & Co. | 65.01B |
| Pfizer | 62.58B |
| AstraZeneca | 58.74B |
| Novartis AG | 56.67B |
| Sanofi | 54.85B |
| Novo Nordisk | 48.59B |
| Bristol-Myers Squibb Company | 48.19B |
| GSK plc | 43.97B |
BIIB News
- 16 hours ago - Biogen Stock Pops After FDA Approves New High-Dose Spinraza For Spinal Muscular Atrophy - Benzinga
- 22 hours ago - US FDA approves higher-dose of Biogen's genetic disorder drug - Reuters
- 22 hours ago - FDA Approves New High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy - GlobeNewsWire
- 2 days ago - Biogen Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting, Showing a Significant Reduction in Skin Disease Activity - GlobeNewsWire
- 5 days ago - Alteogen Enters into a License Agreement with Biogen for Development and Commercialization of Hybrozyme™-Based Subcutaneous Biologics - PRNewsWire
- 10 days ago - Results from Real-World, Long-Term Treatment Persistence with LEQEMBI® (lecanemab-irmb) in the United States Presented at AD/PD™ 2026 - GlobeNewsWire
- 11 days ago - Biogen to Present New Late-Breaking Litifilimab Phase 2 AMETHYST Data in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting - GlobeNewsWire
- 12 days ago - Biogen Inc. (BIIB) Presents at Stifel 2026 Virtual CNS Forum Transcript - Seeking Alpha